Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
2 Winning Growth Stocks That Are Screaming Buys Right Now
The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...
Ozempic for all, Zepbound is back, and the top CEO pay: Pharma news roundup
The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
U.S. Dollar Index Extends Gains, BoE Governor Bailey Remarks Weighs On GBP/USD
The US Dollar Index has seen a strong rally this week, fueled by expectations of a 25 bps Fed rate cut in November and ...
3-Stock Lunch: Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Is Hims & Hers rally at risk as GLP-1 shortages ease?
Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
Lilly's weight-loss, diabetes drugs no longer in shortage, pressuring Hims and Hers' stock
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...